Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment. Additionally, we push our ICOpre deal estimate forward from Q4 2024e to Q1 2025e.
ANNONS
Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment. Additionally, we push our ICOpre deal estimate forward from Q4 2024e to Q1 2025e.